Biosimilars and interchangeable biologics: News to watch October 06, 2016 By Aubrey Westgate Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain. Five specialty pharmaceutical trends to watch October 05, 2016 By Aubrey Westgate Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar. FDA approves biosimilar to Humira September 26, 2016 By Christine Blank FDA’s pace of biosimilar approvals is picking up, as it approved two major drugs for rheumatoid arthritis and other inflammatory diseases in the past month. FDA approves etanercept biosimilar for psoriasis, psoriatic arthritis September 21, 2016 By Lisette Hilton The FDA approved the biosimilars Erelzi for plaque psoriasis and Enbrel for psoriatic arthritis. Predictions for biosimilars: How market access will play out Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars. What the new biosimilar means for U.S. healthcare September 09, 2016 By Christine Blank Physicians and pharmacists welcomed FDA’s recent approval of etanercept-szzs (Erelzi), a biosimilar to Amgen’s top-selling Enbrel for rheumatoid arthritis, plaque psoriasis, and other inflammatory conditions. Biosimilar naming method questioned September 09, 2016 By Christine Blank FDA’s method for naming biosimilars and interchangeable biologics came under fire long before the first biosimilar, Zarxio, was approved last spring. New biosimilar for RA to save millions September 08, 2016 By Christine Blank FDA’s approval of a new biosimilar—the third FDA-approved biosimilar—stands to save the US healthcare system millions of dollars. Remicade will now have a biosimilar August 24, 2016 By Tracey Walker Expert: Expectations are high that biosimilars can control overall biologic cost growth. Four things executives need to know to combat rising drug spend Executives need to ask themselves four key questions to mitigate the negative impact of rising drug costs.